The Top 5 Biosimilar Articles From SABCS 2020

January 31, 2021

Here are the top 5 biosimilar articles from SABCS 2020.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

The 2020 San Antonio Breast Cancer Symposium (SABCS) was held from December 8 to December 12, 2020. During the virtual conference, we covered study presentations that showed the potential for oncology biosimilars, particularly trastuzumab products, in the breast cancer space.

Here are the top 5 biosimilar articles from SABCS 2020.

Number 5: Studies of trastuzumab biosimilars have improved understanding of these medicines as monotherapy and in combination with other agents in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer.

Number 4: Investigators explained the potential for durable antitumor efficacy of a novel trastuzumab biosimilar in patients with HER2-expressing or -driven tumors who have exhausted other treatment options.

Number 3: Investigators have reported pharmacokinetic findings that confirm the biosimilarity of Viatris’ trastuzumab biosimilar candidate (Ogivri) to reference Herceptin.

Number 2: A study of the trastuzumab biosimilar ABP 980 (Kanjinti) in Europe found strong uptake patterns, according to an abstract presentation.

Number 1: Investigators studying trastuzumab biosimilar savings and use rates across different disease settings in HER2-positive breast cancer observed dramatically increased usage of biosimilars and said payer policy appears to have contributed to higher biosimilar utilization.

To read all of these articles and more, visit centerforbiosimilars.com.